A randomized phase 2 study of ARQ 197 [ArQule] versus gemcitabine in treatment-naive patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma.
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2012
At a glance
- Drugs Gemcitabine; Tivantinib
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 20 Jul 2012 Actual patient number changed from 72 to 43 as reported by ClinicalTrials.gov.
- 01 May 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.